DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Copaxone (Glatiramer Acetate) - Summary

 
 



COPAXONE SUMMARY

COPAXONE

COPAXONE® is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE®, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.

COPAXONE® Injection is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.


See all Copaxone indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Copaxone (Glatiramer)

Hot Topics: Role of MRI in Multiple Sclerosis Management
Source: MedPageToday.com - medical news plus CME for physicians [2014.12.12]
(MedPage Today) -- A revolution in diagnosis and subsequent monitoring.

Hot Topics: Vitamin D in Multiple Sclerosis
Source: MedPage Today Neurology [2014.12.11]
(MedPage Today) -- Vitamin D and MS are clearly connected, but do supplements help?

Toxin from tobacco smoke could increase pain in spinal cord injury and worsen multiple sclerosis
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.12.08]
A neurotoxin called acrolein found in tobacco smoke that is thought to increase pain in people with spinal cord injury has now been shown to accumulate in mice exposed to the equivalent of 12...

Chemical compound identified that decreases effects of multiple sclerosis
Source: Endocrinology News From Medical News Today [2014.12.04]
UC Riverside-led mouse study shows the ligand indazole chloride improves motor function, imparting therapeutic benefits even when treatment is initiated at the peak of disease.

New research finds the first evidence of a rogue protein in multiple sclerosis
Source: Biology / Biochemistry News From Medical News Today [2014.12.03]
In a new study published in the journal Frontiers in Neurology, a team of researchers led by the University of Surrey, have identified a rogue protein in multiple sclerosis, which attacks the...

more news >>

Published Studies Related to Copaxone (Glatiramer)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. [2013]
The phase III, multicenter, randomized, placebo-controlled PreCISe trial assessed glatiramer acetate (GA) effects in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS). To assess the neuroprotective effect of GA in a subset of patients in the PreCISe trial, we used proton magnetic resonance spectroscopy (MRS) to measure N-acetylaspartate (NAA), a marker of neuronal integrity, in a large central volume of brain...

Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]
OBJECTIVE: To compare interferon beta-1b (IFNbeta-1b) and glatiramer acetate (GA) on new lesion (NL) (gadolinium-enhancing, new T2) evolution into permanent black holes (PBH)--a marker of irreversible tissue damage--in patients with relapsing-remitting multiple sclerosis (RRMS)... CONCLUSION: IFNbeta-1b affected PBH development to a similar or better extent than GA. IFNbeta-1b favorably influences an MRI outcome indicative of permanent tissue destruction in the brains of patients with multiple sclerosis. Classification of evidence: This study provides Class III evidence that IFNbeta-1b is associated with a reduction in MRI PBH formation and evolution compared with GA between years 1 and 2 of treatment.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. [2011.01]
OBJECTIVE: To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg compared to a 20mg dose... INTERPRETATION: In relapsing-remitting MS patients, both the currently-approved GA 20 mg and 40 mg doses were safe and well-tolerated, with no gain in efficacy for the higher dose. Copyright (c) 2010 American Neurological Association.

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. [2010.11]
Daily glatiramer acetate (GA) 20 mg/1.0 mL is a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). To reduce the occurrence of injection pain and local injection site reactions (LISRs), a reduced volume formulation of GA was developed.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. [2010.03]
The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole disease-modifying therapy... There were no long-term safety issues.

more studies >>

Clinical Trials Related to Copaxone (Glatiramer)

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation [Active, not recruiting]
The purpose of this study is to evaluate the effects of Copaxone injections in retinal function and integrity in diabetic patients who underwent pan-retinal photocoagulation.

Treatment of Multiple Sclerosis With Copaxone and Albuterol [Active, not recruiting]
The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).

MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.

Efficacy and Safety of GTR in Comparison to Copaxone´┐Ż [Recruiting]
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS [Recruiting]
The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS) and (2) to explore the changes in lymphocyte populations in the CNS as a consequence of treatment with rituximab followed by chronic GA therapy.

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis. [Completed]
It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

more trials >>

Reports of Suspected Copaxone (Glatiramer) Side Effects

Multiple Sclerosis Relapse (136)Dyspnoea (107)Urticaria (69)Injection Site Pain (52)Convulsion (51)Nausea (48)Injection Site Reaction (46)Flushing (44)Chest Pain (42)Immediate Post-Injection Reaction (41)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 3 ratings/reviews, Copaxone has an overall score of 8.67. The effectiveness score is 8 and the side effect score is 7.33. The scores are on ten point scale: 10 - best, 1 - worst.
 

Copaxone review by 49 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   relapsing/remitting multiple sclerosis
Dosage & duration:   20 mg taken every day for the period of 7 years
Other conditions:   osteoporosis, migraine headache, spastic bladder
Other drugs taken:   Ditropan 15 mg, Wellbutrin 300 mg
  
Reported Results
Benefits:   It reduces the frequency of episodes of relapsing/remitting multiple sclerosis.
Side effects:   The most common side effects are reactions at the injection site, which I have had, especially at the beginning of treatment. These are redness, a lump or firmness, soreness, or itching at the site of injection. Once I developed a permanent depression at an injection site, which is caused by a localized destruction of fat tissue. Some patients (I never have) develop a short term reaction experienced immediately after injecting this medicine. This reaction includes a feeling of warmth and/or redness known as flushing, chest tightness or pain with heart palpatations, anxiety, and trouble breathing. These symptoms may last a few minutes then go away by themselves without any further problems. Each package of Copaxone contains a complete list of possible side effects, or you may obtain this list from your doctor or pharmacist.
Comments:   Each single use blister pack of Copaxone contains one prefilled syringe containing 20 mg of Copaxone (glatiramer acetate) which the patient self administers subcutaneously, in the fatty layer of skin, once a day. It is important to rotate injection sites daily.

 

Copaxone review by 28 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Multiple Sclerosis
Dosage & duration:   20mg taken once a day/everyday for the period of 2 months
Other conditions:   endometriosis, migraines
Other drugs taken:   Ambien, celexa
  
Reported Results
Benefits:   Peace of mind that I am doing something to decrease the MS progression.
Side effects:   Site reactions: pain, redness, lumps, flush of heat, itchiness
Comments:   I was on copaxone over a year ago and quit because I found the reactions unbearable. My health has declined and I changed doctors and now that I have found the confidence to accept my disease and become more proactive, I have begun applying heat to the site prior to injection. The pain from the shots have practically disappeared. I actually purchased a massager (heart massager from pure romance) that self heats and I don't have to do so much work prior to injection. I still get large red lumps if I don't put ice on it after the injection.

 

Copaxone review by 28 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Multiple Sclerosis
Dosage & duration:   20mg taken once a day/everyday for the period of 2 months
Other conditions:   endometriosis, migraines
Other drugs taken:   Ambien, celexa
  
Reported Results
Benefits:   Peace of mind that I am doing something to decrease the MS progression.
Side effects:   Site reactions: pain, redness, lumps, flush of heat, itchiness
Comments:   I was on copaxone over a year ago and quit because I found the reactions unbearable. My health has declined and I changed doctors and now that I have found the confidence to accept my disease and become more proactive, I have begun applying heat to the site prior to injection. The pain from the shots have practically disappeared. I actually purchased a massager (heart massager from pure romance) that self heats and I don't have to do so much work prior to injection. I still get large red lumps if I don't put ice on it after the injection.

See all Copaxone reviews / ratings >>

Page last updated: 2014-12-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014